Interacciones de Pemetrexed

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Ácido mefenámico, Interacciones medicamentosas)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Celecoxib, Interacciones medicamentosas)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Diclofenaco, Interacciones medicamentosas)

Avoid diclofenac sodium/misoprostol for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Diclofenaco y misoprostol, Interacciones medicamentosas)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Fenoprofeno, Interacciones medicamentosas)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Flurbiprofeno, Interacciones medicamentosas)

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (etiqueta de Pemetrexed, Advertencias y precauciones)

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (etiqueta de Pemetrexed, Advertencias y precauciones)

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (etiqueta de Pemetrexed, Advertencias y precauciones)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Indometacina, Interacciones medicamentosas)

In patients with creatinine clearance below 45 mL/min, the concomitant administration of meloxicam with pemetrexed is not recommended. (etiqueta de Meloxicam, Interacciones medicamentosas)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Naproxeno, Interacciones medicamentosas)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Oxaprozina, Interacciones medicamentosas)

In patients with creatinine clearances between 45 mL/min and 79 mL/min, avoid administration of ibuprofen for 2 days before, the day of, and 2 days following administration of PEMFEXY. (etiqueta de Pemetrexed, Advertencias y precauciones)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Piroxicam, Interacciones medicamentosas)

Dihydrofolate Reductase (DHFR) Inhibitors : Avoid concomitant use (e.g., trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (etiqueta de Sepiapterina, Interacciones medicamentosas)

NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

Initiate supplementation with oral folic acid and intramuscular vitamin B 12 to reduce the severity of hematologic and gastrointestinal toxicity of PEMFEXY. (etiqueta de Pemetrexed, Advertencias y precauciones)

Pemetrexed Clinical Impact : Concomitant use of naproxen and esomeprazole magnesium delayed-release tablets and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information). (etiqueta de Naproxeno y esomeprazol, Interacciones medicamentosas)

Clinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to increased toxicity and mortality. (etiqueta de Pazopanib, Advertencias y precauciones)

Initiate supplementation with oral folic acid and intramuscular vitamin B 12 to reduce the severity of hematologic and gastrointestinal toxicity of PEMFEXY. (etiqueta de Pemetrexed, Advertencias y precauciones)

…(38% versus 23%), thrombocytopenia (9% versus 5%), febrile neutropenia (9% versus 0.6%), and neutropenic infection (6% versus 0) were higher in patients who received pemetrexed plus cisplatin without vitamin supplementation as compared to patients who were fully supplemented with folic acid and vitamin B 12 prior to and throughout pemetrexed plus cisplatin treatment. (etiqueta de Pemetrexed, Advertencias y precauciones)